Prefer Glenmark Pharma: Sudarshan Sukhani

Prefer Glenmark Pharma, says Sudarshan Sukhani, s2analytics.com.

Sukhani told CNBC-TV18, "Glenmark Pharma is the preferred one. I think there is more potential in it."
The company's trailing 12-month (TTM) EPS was at Rs 7.86 per share. (Sep, 2012). The stock's price-to-earnings (P/E) ratio was 66.22. The latest book value of the company is Rs 80.74 per share. At current value, the price-to-book value of the company was 6.45. The dividend yield of the company was 0.38%. Disclosure: I do not have any position in stock, nothing in the Nifty.